Cytophenix Pty Ltd

Cytophenix Pty Ltd, based in Australia, specializes in developing rapid cellular therapies targeting immune system dysfunction and cellular regeneration, enhancing immune responses while minimizing side effects. Cytophenix is focused on creating advanced therapies for immune dysfunction and regeneration. Founded in 2023 in Perth, Australia, the company raised AUD 1. 3 mn in its latest funding round on October 2025, to support its growth initiatives.

Cytophenix specializes in advanced cellular therapies that aim to address significant medical challenges related to immune system dysfunction and cellular regeneration. Their core product offerings include immunomodulatory agents designed to enhance the body’s immune response while minimizing adverse effects. These therapies target a variety of conditions, including autoimmune disorders and cancer, providing innovative solutions for both healthcare providers and patients. The company’s client base encompasses hospitals, research institutions, and specialty clinics primarily located in North America and Europe.

By focusing on collaboration with healthcare professionals, Cytophenix aims to deliver therapies that improve patient outcomes and enhance overall quality of life. Cytophenix generates revenue through a structured model that includes direct sales to healthcare facilities and partnerships with pharmaceutical distributors. Transactions may involve supply agreements where healthcare providers procure Cytophenix’s immunomodulatory agents for patient treatment protocols. Pricing plans are tailored to the specific needs of clients, with potential options for bulk purchasing.

The flagship products are positioned to meet the demand in both B2B and direct-to-consumer markets, allowing for flexible engagement with varied client types. This model supports the company's growth by ensuring that its cutting-edge therapies are accessible to a broad range of end users. In October 2025, Cytophenix raised AUD 1. 3 mn in pre-seed funding to strengthen international stakeholder relationships and initiate pilot trials to expedite its go-to-market strategy.

The company aims to introduce new products targeting diverse immune system conditions while expanding into North American and European markets by late 2026. The recent funding will support these initiatives and strengthen its operational capabilities.